Different stages of primary Sjögren's syndrome involving lymphotoxin and type 1 IFN

Journal of Immunology

Volumn 191, Issue 2, 2013, Pages 608-613

  Shen, Long ^a   Suresh, Lakshmanan ^b,c   Malyavantham, Kishore ^c   Kowal, Przemek ^c   Xuan, Jingxiu ^a   Lindemann, Matthew J ^c   Ambrus, Julian L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c IMMCO Diagnostics Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 14; LYMPHOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; GENE REARRANGEMENT; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IN VIVO STUDY; INTERFERON PRODUCTION; LACRIMAL GLAND DISEASE; MOUSE; NONHUMAN; PAROTID GLAND DISEASE; PRIORITY JOURNAL; SJOEGREN SYNDROME;

EID: 84880119394     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203440     Document Type: Article

References (38)

1. Fox, R. I., F. V. Howell, R. C. Bone, and P. Michelson. 1984. Primary Sjogren syndrome: clinical and immunopathologic features. Semin. Arthritis Rheum. 14: 77-105. (Pubitemid 15218505)
2. Voulgarelis, M., A. G. Tzioufas, and H. M. Moutsopoulos. 2008. Mortality in Sjögren's syndrome. Clin. Exp. Rheumatol. 26(5, Suppl. 51): S66-S71.
3. Gottenberg, J. E., N. Cagnard, C. Lucchesi, F. Letourneur, S. Mistou, T. Lazure, S. Jacques, N. Ba, M. Ittah, C. Lepajolec, et al. 2006. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl. Acad. Sci. USA 103: 2770-2775.
4. Nikolov, N. P., and G. G. Illei. 2009. Pathogenesis of Sjögren's syndrome. Curr. Opin. Rheumatol. 21: 465-470.
5. Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392. (Pubitemid 44354221)
6. Soyfoo, M. S., S. Steinfeld, and C. Delporte. 2007. Usefulness of mouse models to study the pathogenesis of Sjögren's syndrome. Oral Dis. 13: 366-375. (Pubitemid 46934581)
7. Lee, B. H., A. E. Gauna, K. M. Pauley, Y. J. Park, and S. Cha. 2012. Animal models in autoimmune diseases: lessons learned from mouse models for Sjögren's syndrome. Clin. Rev. Allergy Immunol. 42: 35-44.
8. Shen, L., C. Zhang, T.Wang, S. Brooks, R. J. Ford, Y. C. Lin-Lee, A. Kasianowicz, V. Kumar, L. Martin, P. Liang, et al. 2006. Development of autoimmunity in IL-14α-transgenic mice. J. Immunol. 177: 5676-5686.
9. Shen, L., L. Suresh, H. Li, C. Zhang, V. Kumar, O. Pankewycz, and J. L. Ambrus, Jr. 2009. IL-14α, the nexus for primary Sjögren's disease in mice and humans. Clin. Immunol. 130: 304-312.
10. Shen, L., L. Suresh, J. Wu, J. Xuan, H. Li, C. Zhang, O. Pankewycz, and J. L. Ambrus, Jr. 2010. A role for lymphotoxin in primary Sjögren's disease. J. Immunol. 185: 6355-6363.
11. Shen, L., L. Suresh, M. Lindemann, J. Xuan, P. Kowal, K. Malyavantham, and J. L. Ambrus, Jr. 2012. Novel autoantibodies in Sjogren's syndrome. Clin. Immunol. 145: 251-255.
12. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921. (Pubitemid 24245635)
13. Pijpe, J., W. W. Kalk, H. Bootsma, F. K. Spijkervet, C. G. Kallenberg, and A. Vissink. 2007. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann. Rheum. Dis. 66: 107-112. (Pubitemid 46044868)
14. Bournia, V. K., and P. G. Vlachoyiannopoulos. 2012. Subgroups of Sjögren syndrome patients according to serological profiles. J. Autoimmun. 39: 15-26.
15. Hernández-Molina, G., G. Leal-Alegre, and M. Michel-Peregrina. 2011. The meaning of anti-Ro and anti-La antibodies in primary Sjögren's syndrome. Autoimmun. Rev. 10: 123-125.
16. Finkelman, F. D., A. Svetic, I. Gresser, C. Snapper, J. Holmes, P. P. Trotta, I. M. Katona, and W. C. Gause. 1991. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174: 1179-1188.
17. Candon, S., J. E. Gottenberg, D. Bengoufa, L. Chatenoud, and X. Mariette. 2009. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity. Ann. Rheum. Dis. 68: 1208-1212.
18. Nordmark, G., G. V. Alm, and L. Rönnblom. 2006. Mechanisms of disease: primary Sjögren's syndrome and the type I interferon system. Nat. Clin. Pract. Rheumatol. 2: 262-269.
19. Terawaki, S., S. Chikuma, S. Shibayama, T. Hayashi, T. Yoshida, T. Okazaki, and T. Honjo. 2011. IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186: 2772-2779.
20. Ferraccioli, G. F., F. Salaffi, S. De Vita, L. Casatta, C. Avellini, M. Carotti, C. A. Beltrami, C. Cervini, and E. Bartoli. 1996. Interferon α-2 (IFNα2) increases lacrimal and salivary function in Sjögren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin. Exp. Rheumatol. 14: 367-371. (Pubitemid 26257587)
21. Roescher, N., P. P. Tak, and G. G. Illei. 2010. Cytokines in Sjögren's syndrome: potential therapeutic targets. Ann. Rheum. Dis. 69: 945-948.
22. Ship, J. A., P. C. Fox, J. E. Michalek, M. J. Cummins, and A. B. Richards. 1999. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-α administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J. Interferon Cytokine Res. 19: 943-951. (Pubitemid 29406651)
23. McRae, B. L., L. J. Picker, and G. A. van Seventer. 1997. Human recombinant interferon-β influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur. J. Immunol. 27: 2650-2656. (Pubitemid 27453856)
24. Banks, T. A., S. Rickert, and C. F. Ware. 2006. Restoring immune defenses via lymphotoxin signaling: lessons from cytomegalovirus. Immunol. Res. 34: 243-254.
25. Martin, D. N., I. S. Mikhail, and O. Landgren. 2009. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk. Lymphoma 50: 541-550.
26. Theander, E., G. Henriksson, O. Ljungberg, T. Mandl, R. Manthorpe, and L. T. H. Jacobsson. 2006. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis. 65: 796-803. (Pubitemid 43799181)
27. Peters, M., J. L. Ambrus, Jr., A. Zheleznyak, D. Walling, and J. H. Hoofnagle. 1986. Effect of interferon-alpha on immunoglobulin synthesis by human B cells. J. Immunol. 137: 3153-3157. (Pubitemid 17181682)
28. Hibbert, L., and G. R. Foster. 1999. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J. Interferon Cytokine Res. 19: 309-318. (Pubitemid 29210678)
29. Emamian, E. S., J. M. Leon, C. J. Lessard, M. Grandits, E. C. Baechler, P. M. Gaffney, B. Segal, N. L. Rhodus, and K. L. Moser. 2009. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun. 10: 285-296.
30. Harigai, M., M. Kawamoto, M. Hara, T. Kubota, N. Kamatani, and N. Miyasaka. 2008. Excessive production of IFN-γ in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J. Immunol. 181: 2211-2219.
31. Yao, Y. H., L. Richman, B. W. Higgs, C. A. Morehouse, M. de los Reyes, P. Brohawn, J. L. Zhang, B. White, A. J. Coyle, P. A. Kiener, and B. Jallal. 2009. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60: 1785-1796.
32. Pers, J. O., V. Devauchelle, C. Daridon, B. Bendaoud, R. Le Berre, A. Bordron, P. Hutin, Y. Renaudineau, M. Dueymes, S. Loisel, et al. 2007. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum. 56: 1464-1477. (Pubitemid 46764075)
33. Daridon, C., V. Devauchelle, P. Hutin, R. Le Berre, C. Martins-Carvalho, B. Bendaoud, M. Dueymes, A. Saraux, P. Youinou, and J. O. Pers. 2007. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 56: 1134-1144. (Pubitemid 46608638)
34. Lavie, F., C. Miceli-Richard, M. Ittah, J. Sellam, J. E. Gottenberg, and X. Mariette. 2008. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand. J. Immunol. 67: 185-192.
35. Graninger, W. B., M. Seto, B. Boutain, P. Goldman, and S. J. Korsmeyer. 1987. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J. Clin. Invest. 80: 1512-1515. (Pubitemid 18027800)
36. Ford, R. J., L. Shen, Y. C. Lin-Lee, L. V. Pham, A. Multani, H. J. Zhou, A. T. Tamayo, C. Zhang, L. Hawthorn, J. K. Cowell, and J. L. Ambrus, Jr. 2007. Development of a murine model for blastoid variant mantle-cell lymphoma. Blood 109: 4899-4906. (Pubitemid 46827787)
37. Craxton, A., K. E. Draves, A. Gruppi, and E. A. Clark. 2005. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J. Exp. Med. 202: 1363-1374. (Pubitemid 41668739)
38. Fletcher, C. A., A. P. Sutherland, J. R. Groom, M. L. Batten, L. G. Ng, J. Gommerman, and F. Mackay. 2006. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur. J. Immunol. 36: 2504-2514. (Pubitemid 44420606)